Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24295241 | 0.82 | HCAR2 (0.31) | — | |
| SCHEMBL827192 | 0.82 | GABRA1 (0.35) | TSHRGABRA1GABRB2 | |
| SCHEMBL14765667 | 0.79 | TSHR (0.39) | TSHRRORC | |
| SCHEMBL22426458 | 0.77 | TSHR (0.38) | TSHRRORC | |
| SCHEMBL23332701 | 0.77 | TSHR (0.38) | TSHRRORC | |
| SCHEMBL22426583 | 0.74 | TSHR (0.35) | TSHRRORC | |
| SCHEMBL22435596 | 0.74 | TSHR (0.35) | TSHRRORC | |
| SCHEMBL27310316 | 0.74 | RORC (0.37) | TSHRRORC | |
| SCHEMBL20077046 | 0.71 | ALOX15 (0.30) | — | |
| SCHEMBL24295356 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414770-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180134716-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414770-B2 | Compounds and methods for inhibiting mitotic progression | AURKC, AURKA, AURKB | TSHR 4809/4885RORC 1686/4885GABRA1 4822/4885 |
| US-20180134716-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | TSHR 4809/4885RORC 1686/4885GABRA1 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.